German biotech firm BioNTech on Monday said that second-quarter revenues more than doubled to 261 million euros ($302 million ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

BioNTech also laid off 63 employees in June in conjunction with the discontinuation of its cell therapy manufacturing ...

The study tests BNT327, an investigational drug administered via intravenous infusion, in combination with standard chemotherapy drugs like etoposide, carboplatin, paclitaxel, and topotecan. The goal ...

Analysts have recently evaluated BioNTech and provided 12-month price targets. The average target is $134.42, accompanied by ...

This study could significantly impact BioNTech’s stock performance and investor sentiment, especially if the results demonstrate a breakthrough in breast cancer treatment. The involvement of ...

On August 1, 2025, a UK Court of Appeal upheld the validity of Moderna’s European Patent No. 3,590,949 (“EP’949”) in a dispute with Pfizer ...

Pfizer-BioNTech has applied for full approval of its Covid-19 vaccine with the FDA. The vaccine would be the first Covid-19 vaccine approved for use in the U.S.

BioNTech stock, a leader in messenger RNA technology and Pfizer’s Covid-19 vaccine partner, declined by almost 31% over the last month, considerably underperforming the S&P 500 which remained ...

Türeci co-founded BioNTech, a German company that partnered with pharmaceutical giant Pfizer to develop the first U.S.-authorized COVID-19 vaccine.

BioNTech, a leader in messenger RNA technology and Pfizer’s Covid-19 vaccine partner, has seen its stock decline by almost 9.4% over the last week (five trading days) and by about 17% over the ...

Pfizer and BioNTech are confident they can have a vaccine against the novel coronavirus ready for regulatory approval by the middle of October or early November, BioNTech CEO and co-founder Ugur ...